Findings
========

Non-coding RNAs, including microRNAs (miRNAs), are increasingly the target of biomarker development \[[@B1]\]. These molecules play a central role in gene expression regulation, in particular at the posttranscriptional and homeostatic levels \[[@B2],[@B3]\], and have been detected in specimen matrices used for cancer biomarker development, including solid tissues, urine, sera, and blood. \[[@B4]-[@B6]\]. Indeed, miRNAs have been developed as informative markers for breast \[[@B6]\], colorectal \[[@B7]\] and ovarian cancers \[[@B8],[@B9]\]. As biomarkers, circulating miRNAs (c-miRNAs) may be preferable to miRNAs located in solid tumor tissues due to their accessibility, stability during storage, and the increased specificity and sensitivity of multiplexed assays i.e., approaches that allow the analysis of panels of c-miRNAs assembled together to identify miRNA signatures. Discovery of c-miRNAs biomarkers frequently begins with high throughput approaches such as microarrays or small RNA-Seq with subsequent verification by quantitative reverse transcription PCR (qPCR). The qPCR represents a confirmatory step that allows either absolute or relative quantitation of miRNAs expression, by integrating a standard curve or a reference control gene in the analysis, respectively \[[@B10]\].

In this short report we present a modified method for qPCR detection of c-miRNAs in plasma from human blood, collected using an anticoagulant, such as lithium heparin. Whereas most macromolecular constituents of plasma and serum are the same, and both are devoid of platelets, red and white blood cells, sera and plasma can be used interchangeably in serological analysis targeting antibodies or antigens \[[@B11]\]. However, plasma - unlike serum - retains the coagulation cascade clotting factors and fibrinogen, and problematically, exogenous anticoagulant(s) that block the blood from clotting. This presence of extraneous anticoagulants can interfere with the qPCR, including reverse transcription of the RNA to cDNA and amplification of the target cDNA \[[@B12]-[@B14]\]. Here we present an alternative to conventional approaches to overcome the inhibition from residual heparin in qPCR to detect c-miRNAs in plasma. These modifications to previously reported methods not only improved the qPCR but also reduced costs and streamlined the analysis by shortening processing time, and, thereby reduced the likelihood of RNA degradation.

Duplicate RT reactions were performed along with duplicate qPCRs for all the samples. The findings were compared with informative reports from others dealing with detection of c-miRNAs in sera. In ongoing studies, we plan to employ this modified protocol in discovery and validation of c-miRNAs as biomarkers for liver fluke induced cholangiocarcinoma (CCA) \[[@B15]\], with plasma collected in a longitudinal study and biobanked at -80°C. RNA was recovered from plasma (250 μl) using the QIAamp circulating nucleic acids kit (Qiagen) following the manufacturer's standard protocol. In most cases, the RNA was reverse transcribed using the miScript II RT Kit (Qiagen) in HiSpec buffer and cDNA screened on custom miScript miRNA PCR Arrays (SA Biosciences). qPCR was performed with SYBR Green PCR Master Mix (miScript, Qiagen), a thermocycler (iCycler, Bio-Rad, Hercules, CA) fitted with real time detector (Bio-Rad iQ5), and the following thermal cycling: activation at 95°C, 15 min; 40 cycles of denaturation, 15 sec, 94°C, annealing, 30 sec 55°C, extension, 30 sec, 70°C); melting curve analysis, 81 cycles of 55°C, 20 sec dwell.

In contrast to studies using sera, miRNAs were not detectable from plasma (Figure [1](#F1){ref-type="fig"}A and B), including miRTC controls (miRTC: Reverse transcriptase qPCR; Qiagen) at 45 thermal cycles while PPC (Positive qPCR Controls, Qiagen) C~t~ values ranged from 18 and 20. To address this problem, we extracted RNA using the miRNeasy serum/blood plasma kit (Qiagen), which uses phenol and chloroform, and as a positive control, spiked plasma with *C. elegans* miR-39 mimic (Qiagen) \[[@B16]\]. The yield of RNA derived from plasma in both the QIAamp and miRNAeasy methods was 8-12 ng/μl, and was of similar quality to that we have recovered from sera \[[@B17]\], although RNA from plasma exhibited lower 260/230 ratios, (\<0.7) with the miRNeasy kit. However, when RNA isolated using miRNeasy was subjected to qPCR, the C~t~ values did not improve, including for control *C. elegans* miR-39 which was employed to spike plasma (Figure [1](#F1){ref-type="fig"}A and B). This suggested interference, likely during reverse transcription; notably, the matrix of the original stored specimens - plasma versus serum - represented the only apparent difference from the previous analysis \[[@B17]\]. In reviewing the literature \[[@B12],[@B13],[@B18],[@B19]\], a modified protocol was outlined for testing to overcome the residual heparin interference.

![**Comparison of qRT-PCR controls obtained from RNA with and without treatment with*Bacteroides*heparinase I.** Panel **A**: Workflow of conditions tested for serum and plasma. Serum under standard conditions and plasma treated with *Bacteroides* heparinase I during the reverse transcription (RT) of RNA to cDNA yielded the most consistent signals. The colors indicate the level of performance -- poor (red); fair (yellow); good (green). Panel **B**. Comparison of Ct values for qPCR controls obtained from RNA with and without treatment with *Bacteroides* heparinase I. Positive PCR Control (PPC) denoted a positive qPCR control and miRTC denotes reverse transcriptase controls. The plasma was spiked with *C. elegans* miR-39. Results (duplicate readings) for replicate samples for each treatment are shown. Optimization steps (Experiments 1 and 2) were carried out with plasma donated by the same persons. \[Selected treatment conditions were confirmed using additional plasma (Figure [3](#F3){ref-type="fig"}, Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1).\] Panels **C-E**, Threshold cycles (C~t~ ) for qPCR controls with and without heparinase I. miRTC (panel **C**), PPC **(D)**, and miR-cel-39 **(E)** curves of Relative Fluorescent Units RFU (Y-axis) versus cycles (X-axis) for (left to right): 1) 6 U *Bacteroides* heparinase I during RT, 2) 6 U *Bacteroides* heparinase I treatment prior to RT, 3) 0.6 U *Bacteroides* heparinase I before RT, and 4) no treatment in duplicate (not visible along X-axis in Panel **C, E**). Panels **F-H**: miRTC curves of RFU (Y-axis) versus cycle time (X-axis) for (left to right): 1) 12 U, 6 μl; 2) 12 U, 3 μl; 3) 6 U, 3 μl; and 4) 0.6 U, 3 μl for Units of *Bacteroides* heparinase I and volume of RNA, respectively for miRTC (panel **F**), PPC **(G)** and miR-cel-39 **(H)**. Condition four yielded no curve for miR-cel-39 in panel **H** (presented on X-axis).](2050-7771-2-13-1){#F1}

The first modification included in the approach for processing plasma (Experiment 1, Figure [1](#F1){ref-type="fig"}A and B) was replacement of *Flavobacterium heparinum* heparinase I with *Bacteroides* heparinase I (New England BioLabs) during RT (Experiment 1, Figure [1](#F1){ref-type="fig"}A and B). *Bacteroides* heparinase I cleaves 2-*O*-sulfated glucuronic acid residues in heparin in addition to the glycosidic bond between *N*-sulfated hexosamines and 2-*O*-sulfated iduronic acid residues cleaved by heparinase of *F. heparinum*\[[@B18],[@B19]\]. Three reaction conditions were compared: (1) pre-treatment of RNA with *B.* heparinase I; (2) co-treatment of RNA during RT with *B.* heparinase I; and (3) pre-amplification. For pre-treatment of the RNA before RT \[[@B12],[@B13]\], 0.6 U and 6.0 U *Bacteroides* heparinase I were incubated with 3 μl RNA for 2 h at 25°C then subsequently reverse transcribed. For co-treatment, the miScript II RT reaction (reaction volume, 20 μl) included 6 U *Bacteroides* heparinase I, 4 μl HiSpec 5× buffer, 2 μl 10× nucleic acids, 2 μl reverse transcriptase mix, and 3 μl RNA. For pre-amplification, the RT reaction was carried out according to the manufacturer's protocol with the miScript Pre-AMP PCR Kit (Qiagen) for 12 cycles. In all cases, reverse transcription was carried out at 37°C for 1 h after which the RT was inactivated at 95°C, 5 min. The reaction products were diluted to 200 μl with water, stored on wet ice or at -80°C and analyzed by qPCR on miScript miRNA QA PCR Arrays (SA Biosciences). Minimal or no improvement was seen with the pre-amplification kit for the miRTC controls. By contrast, incubation with *Bacteroides* heparinase I before and during RT resulted in detectable miRTC values, with optimal amplification observed after inclusion of 6 U *Bacteroides* heparinase I during RT: miRTC, C~t~ \~28 (Figure [1](#F1){ref-type="fig"}B and C), PPC (Figure [1](#F1){ref-type="fig"}B and D), and miR-39, C~t~ \~26.5 (Figure [1](#F1){ref-type="fig"}B and E).

Because it eliminated one reaction step and thereby reduced exposure time of the RNA to elevated temperatures, co-treatment or inclusion of *Bacteroides* heparinase I during RT was examined, aiming for further improvement. Four conditions were tested: 0.6 U, 6 U and 12 U of *Bacteroides* heparinase I, with increasing quantities of RNA from 3 to 6 μl (Experiment 2; Figure [1](#F1){ref-type="fig"}A and B). Here C~t~ values were inversely related to the concentration of *Bacteroides* heparinase I (Figure [1](#F1){ref-type="fig"}B). Moreover, using 12 U *Bacteroides* heparinase I with 3 μl and 6 μl RNA resulted in miRTC values that were ≤ 5 cycles less than the positive qPCR controls (PPC) (Figure [1](#F1){ref-type="fig"}B, F, G and H). Last, to determine potentially negative influences of the RNA purification (QIAamp versus miRNeasy) on residual lithium heparin, RNA from QIAamp purifications (3 μl, 6 μl RNA) was also tested. In this case, QIAamp purifications were likely to have included more residual heparin since the plasma was not subjected to extraction in phenol-chloroform, and was in turn exposed to 12 U of *Bacteroides* heparinase I during RT. This condition yielded similar signals to matched samples treated as above (Figure [1](#F1){ref-type="fig"}B). To summarize, treatment with 12 U of *Bacteroides* heparinase I during RT at 37°C with 3 μl or 6 μl RNA delivered strong, positive and reproducible qPCR signals, markedly improving outcomes over no treatment or strategies similar to methods reported previously \[[@B12],[@B13]\]. Additionally, co-treatment with *Bacteroides* heparinase I during RT offers the following advantages: 1) streamlines the protocol, without additional steps and reducing process times compared to earlier methods; 2) limits exposure of RNA to deleterious conditions including elevated temperatures for prolonged periods; and 3) improves sensitivity of qPCR compared to no-treatment or other approaches (Figure [2](#F2){ref-type="fig"}).

![**Summary of advantages of the new approach concerning treatment of plasma with*Bacteroides*heparinase I before quantitative to detect c-miRNAs in plasma that improves sensitivity and streamlines performance.**](2050-7771-2-13-2){#F2}

To confirm that this modified method for *Bacteroides* heparinase I improved sensitivity not only with assay and reaction controls, i.e., PPC, miRTC, miR-39, but could also be extrapolated to biomarker discovery, we examined the C~t~ results from a custom miScript miRNA PCR Array (SA Biosciences) across 19 discrete plasma samples. The arrays included 94 miRNA (mature, human) primers that provide potential signatures for cholangiocarcinoma \[[@B20]\]. We used 12 U *Bacteroides* heparinase I during RT and compared this with no-treatment of RNA. Without treatment, miRNAs remained undetected below 45 cycles on the custom miRNA array. By contrast, inclusion of *Bacteroides* heparinase I during RT significantly improved the sensitivity of detection: \~50% of the target miRNAs were detected at ≤ 35 cycles (Figure [3](#F3){ref-type="fig"}). Using this method, RNA from plasma was reproducibility reverse transcribed and amplified despite the presence of residual heparin in the plasma. Further, the miRTC and the ce-miR-39 spiked controls for 19 plasma samples from our investigation of biomarkers for CCA \[[@B20]\] are presented in Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1. To conclude, the method presented here may be applicable to the analysis of miRNAs derived from blood, and should be especially advantageous for plasma from heparinized blood and/or where sera are unavailable.

![**Threshold cycles for qPCR targeting cholangiocarcinoma associated miRNAs in a larger panel of plasma samples.** Percentage of miRNAs based on their C~t~ values (not including the controls, PPC and RTC) from 19 samples of total RNAs isolated from plasma and not treated with *Bacteroides* heparinase I (no treatment) and with *Bacteroides* heparinase I during RT.](2050-7771-2-13-3){#F3}
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###### Additional file 1: Figure S1

Box-and-whisker plot of threshold cycles (main axis) for miRTC and *C. elegans* miR-39 from 19 samples of threshold cycles exposed to *Bacteroides* heparinase I during the reverse transcription. Matched samples not treated with heparinase I failed to yield measurable C~t~ (\>45), except for PPC.
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